Phase 1/2 Study Tests Quizartinib/Venetoclax/Decitabine in FLT3-ITD AML
March 11th 2024Musa Yilmaz, MD, discusses the most recent update of the phase 1/2 study of quizartinib, venetoclax, and decitabine in FLT3-internal tandem duplication mutated acute myeloid leukemia and the background behind this research.
Watch
Advantages of SC HER2 Therapy Over IV Administration in Breast Cancer
March 7th 2024Rebecca A. Shatsky, MD, discusses the advantages of giving patients with HER2-positive breast cancer a subcutaneous injection of targeted therapy compared with the intravenous formulation of trastuzumab and pertuzumab.
Watch